ACRF-funded research teams across Australia have collaborated to develop a remarkable new treatment option for Acute Myeloid Leukaemia (AML) and accelerate it into clinical trials.
AML is a particularly aggressive form of cancer with poor survival rates; although chemotherapy can induce remission there is often a high chance of relapse. However, this new research, published in major international journal Cell Reports, details how a newly developed therapeutic antibody (CSL362) binds to the cancer cells and then recruits the body’s immune system to kill the cancer cells.
Collaboration between the ACRF-funded Centre for Cancer Biology, Adelaide and St Vincent’s Institute of Medical Research, Melbourne, together with biopharmaceutical company CSL Limited has brought about these important findings.
Most importantly, the research demonstrates how targeted therapy can help the immune system kill cancer cells, potentially extending the lives of patients and causing fewer side effects than other treatments.
“It is an exciting time as we move away from conventional method to more targeted, personalised medicine… one that leads to fewer side effects and more effective treatments,” said CCB Co-Director Professor Angel Lopez.
“With clinical trials now underway, the article highlights the importance of fundamental research and the benefits of close collaboration between cancer researchers and the pharmaceutical industry.”
The full article, “Dual mechanism of interluken-3 receptor blockade by an anti-cancer antibody”, can be found here.